Matthew H. Taylor

20.0k total citations · 5 hit papers
173 papers, 6.4k citations indexed

About

Matthew H. Taylor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Matthew H. Taylor has authored 173 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Oncology, 58 papers in Pulmonary and Respiratory Medicine and 31 papers in Molecular Biology. Recurrent topics in Matthew H. Taylor's work include Cancer Immunotherapy and Biomarkers (58 papers), Thyroid Cancer Diagnosis and Treatment (28 papers) and Lung Cancer Treatments and Mutations (27 papers). Matthew H. Taylor is often cited by papers focused on Cancer Immunotherapy and Biomarkers (58 papers), Thyroid Cancer Diagnosis and Treatment (28 papers) and Lung Cancer Treatments and Mutations (27 papers). Matthew H. Taylor collaborates with scholars based in United States, France and Germany. Matthew H. Taylor's co-authors include Corina E. Dutcus, Marcia S. Brose, Vicky Makker, Lori J. Wirth, Bruce Robinson, Daniel E. Stepan, Makoto Tahara, Monika K. Krzyzanowska, Sung‐Bae Kim and Steven I. Sherman and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Matthew H. Taylor

167 papers receiving 6.4k citations

Hit Papers

Lenvatinib versus Placebo in Radioiodine-Refractory Thyro... 2015 2026 2018 2022 2015 2019 2020 2019 2020 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
    2015 1.4k citations Martin Schlumberger, Makoto Tahara et al. New England Journal of Medicine profile →
  2. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    2019 360 citations Vicky Makker, Drew Rasco et al. profile →
  3. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
    2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →
  4. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
    2019 319 citations Matthew H. Taylor, Karen Kelly et al. profile →
  5. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    2020 306 citations Matthew H. Taylor, Vicky Makker et al. Journal of Clinical Oncology profile →

Peers

Matthew H. Taylor
Comparison fields: 5 of 118
  • Oncology 3.5k
  • Pulmonary and Respiratory Medicine 1.6k
  • Endocrinology, Diabetes and Metabolism 1.4k
  • Molecular Biology 1.4k
  • Immunology 1.1k
Replace Lori A. Erickson with:
Lori A. Erickson United States
Maurizio Martini Italy
Maria Luisa Carcangiu Italy
Snjezana Doğan United States
Lori J. Wirth United States
Andréa Varga France
Yoon‐La Choi South Korea
Simion I. Chiosea United States
Shigeki Sekine Japan
Kaarle Franssila Finland
Lori A. Erickson United States View profile →
Citations per field, relative to Matthew H. Taylor
Matthew H. Taylor · 1×
Citations per year, relative to Matthew H. Taylor
Matthew H. Taylor · 1×

Countries citing papers authored by Matthew H. Taylor

Since Specialization
Citations

This map shows the geographic impact of Matthew H. Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew H. Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew H. Taylor more than expected).

Fields of papers citing papers by Matthew H. Taylor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew H. Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew H. Taylor. The network helps show where Matthew H. Taylor may publish in the future.

Co-authorship network of co-authors of Matthew H. Taylor

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew H. Taylor. A scholar is included among the top collaborators of Matthew H. Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew H. Taylor. Matthew H. Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration
2024 ·Molecular Carcinogenesis ·Alice N. Weaver, Wade T. Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S. Gordon, Kerry J. Rodabaugh, Neesha C. Dhani, Prakash Neupane, Matthew H. Taylor, (unknown), (unknown), Nathan R. Miselis, Scott Loughhead, Marshelle Warren, Howard Bernstein, Jens Peter Klußmann, Joaquina Baranda, Antonio Jimeno
2
2
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)
2024 ·Journal for ImmunoTherapy of Cancer ·Margaret K. Callahan, Asim Amin, Frederic J. Kaye, Michael A. Morse, Matthew H. Taylor, Katriina Peltola, Padmanee Sharma, Eileen M. O’Reilly, (unknown), Shaun O’Brien, Marina Tschaika, Dung T. Le
7
3
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
2024 ·Endocrine Related Cancer ·Marcia S. Brose, Jaume Capdevila, Rossella Elisei, Lars Bastholt, Dagmar Führer‐Sakel, Sophie Leboulleux, Iwao Sugitani, Matthew H. Taylor, Zhuoying Wang, Lori J. Wirth, Francis P. Worden, John Bernard, (unknown), (unknown), Shiguang Liu, Martin Schlumberger
4
4
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
2023 ·Journal of Clinical Oncology ·Adnan Khattak, Jeffrey S. Weber, Tarek Meniawy, Matthew H. Taylor, George Ansstas, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark B. Faries, Thuy Tran, (unknown), Theresa Medina, Jennifer Segar, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Elizabeth I. Buchbinder, Robert Meehan, Matteo S. Carlino, (unknown)
50
5
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
2023 ·Journal of Clinical Oncology ·Vicky Makker, Carol Aghajanian, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Mark Messing, Lea Dutta, Corina E. Dutcus, Jie Huang, Emmett V. Schmidt, Robert Orlowski, Matthew H. Taylor
25
6
LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response
2023 ·Annals of Oncology ·Jeffrey S. Weber, Adnan Khattak, Matteo S. Carlino, Ryan J. Sullivan, Jason J. Luke, Tarek Meniawy, Matthew H. Taylor, George Ansstas, (unknown), Meredith McKean, Mark B. Faries, Tam Tran, C. Lance Cowey, Andrew L. Pecora, Theresa Medina, Victoria Atkinson, Geoffrey T. Gibney, Elizabeth I. Buchbinder, Robert Meehan, Georgina V. Long
5
7
1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)
2022 ·Annals of Oncology ·(unknown), (unknown), Aaron S. Mansfield, Matthew H. Taylor, (unknown), Viola W. Zhu, Julien Hadoux, Giuseppe Curigliano, Lori J. Wirth, Elena Garralda, Douglas R. Adkins, (unknown), M-J. Ahn, (unknown), Byoung Chul Cho, (unknown), Teresa Barata, Alena Zalutskaya, Astrid Scalori, Marcia S. Brose
2
8
48MO SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors
2021 ·Annals of Oncology ·(unknown), Joaquina Baranda, Monica Mita, Wade T. Iams, Michael S. Gordon, Matthew H. Taylor, Neesha C. Dhani, Scott Loughhead, (unknown), Ricardo Zwirtes, Martin Kornacker, O. Rosen, Howard Bernstein, Antonio Jimeno
1
9
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer breakdown →
2020 ·Journal of Clinical Oncology ·Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Robert Orlowski, Perminder S. Sachdev, Robert Shumaker, Antonio Casado
359
10
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
2020 ·Blood Advances ·Stephen M. Ansell, Ian W. Flinn, Matthew H. Taylor, Branimir I. Šikić, Joshua Brody, John Nemunaitis, Andrew L. Feldman, Thomas Hawthorne, (unknown), Tibor Keler, Michael Yellin
52
11
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
2020 ·Journal for ImmunoTherapy of Cancer ·Claire F. Verschraegen, Guy Jérusalem, Edward F. McClay, Nicholas Iannotti, Charles H. Redfern, Jaafar Bennouna, (unknown), Karen Kelly, Janice M. Mehnert, John C. Morris, Matthew H. Taylor, David R. Spigel, Ding Wang, H. Grote, Dongli Zhou, Neru Munshi, Marcis Bajars, James L. Gulley
19
12
Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status
2019 ·Head & Neck ·(unknown), Daniel Clayburgh, (unknown), David Sauer, Matthew H. Taylor, Maisie L. Shindo, Lisa M. Coussens, Takahiro Tsujikawa
22
13
A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal
2017 ·Blood ·Christiane Querfeld, John A. Thompson, Matthew H. Taylor, Raju Pillai, Lisa D. Johnson, (unknown), Penka S. Petrova, Robert A. Uger, (unknown), Eric L. Sievers, Oleg E. Akilov
15
14
Subgroup analysis of a phase II multicenter trial of HF10, oncolytic virus immunotherapy, and ipilimumab combination treatment in unresectable or metastatic melanoma patients
2017 ·Annals of Oncology ·Robert H.I. Andtbacka, Merrick I. Ross, Sanjiv S. Agarwala, Matthew H. Taylor, John T. Vetto, Rogerio I. Neves, Adil Daud, Hung T. Khong, Richard S. Ungerleider, Maki Tanaka, Kenneth F. Grossmann
0
15
A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
2017 ·Annals of Oncology ·Chi‐Hang Lee, Vicky Makker, (unknown), Matthew H. Taylor, Corina E. Dutcus, Robert Shumaker, Emmett V. Schmidt, Daniel E. Stepan, (unknown), Robert J. Motzer
22
16
OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC
2017 ·Journal of Thoracic Oncology ·Guy Jérusalem, Franklin Chen, David R. Spigel, Nicholas Iannotti, Edward F. McClay, Charles H. Redfern, Jaafar Bennouna, Matthew H. Taylor, Howard L. Kaufman, Karen Kelly, Vikram K. Chand, Anja von Heydebreck, Claire F. Verschraegen
19
17
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
2016 ·Annals of Oncology ·Matthew H. Taylor, Corina E. Dutcus, Emmett V. Schmidt, Teresa Bagulho, (unknown), Robert Shumaker, Drew Rasco
23
18
Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma
2016 ·Annals of Oncology ·Robert H.I. Andtbacka, Merrick I. Ross, Sanjiv S. Agarwala, Matthew H. Taylor, John T. Vetto, Rogerio I. Neves, Adil Daud, Hung T. Khong, Richard S. Ungerleider, Sophie Van Welden, Maki Tanaka, Kenneth F. Grossmann
3
19
150O Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
2016 ·Annals of Oncology ·David S. Hong, Afshin Dowlati, Howard A. Burris, (unknown), Marcia S. Brose, Anna F. Farago, Todd M. Bauer, Matthew H. Taylor, Alice T. Shaw, Steven G. Smith, Nisha Nanda, Scott Cruickshank, M.C. Cox, Robert C. Doebele
1
20
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer breakdown →
2015 ·New England Journal of Medicine ·Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Steven I. Sherman
1408

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lori A. Erickson Breakdown of academic impact, for papers by Maurizio Martini Breakdown of academic impact, for papers by Maria Luisa Carcangiu Breakdown of academic impact, for papers by Snjezana Doğan Breakdown of academic impact, for papers by Lori J. Wirth Breakdown of academic impact, for papers by Andréa Varga Breakdown of academic impact, for papers by Yoon‐La Choi Breakdown of academic impact, for papers by Simion I. Chiosea Breakdown of academic impact, for papers by Shigeki Sekine Breakdown of academic impact, for papers by Kaarle Franssila
Rankless by CCL
2026